U.S. Markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.83 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.11 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.46
    +2.70 (+2.55%)
     
  • Gold

    1,812.90
    +5.60 (+0.31%)
     
  • Silver

    19.77
    -0.51 (-2.50%)
     
  • EUR/USD

    1.0426
    -0.0057 (-0.5422%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • Vix

    26.70
    -2.01 (-7.00%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.5930%)
     
  • USD/JPY

    135.1750
    -0.5530 (-0.4074%)
     
  • BTC-USD

    19,318.62
    -1,022.19 (-5.03%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Global Diabetic Retinopathy Market Is Expected to Reach $10.78 Billion by 2030: Says AMR

·4 min read
Allied Market Research
Allied Market Research

Surge in the prevalence of diabetes, rise in the geriatric population, growth in incidence of blindness due to diabetes, and increase in focus on awareness that facilitates early diagnosis to control the diseases drive the growth of the global diabetic retinopathy market. Based on type, the proliferative diabetic retinopathy segment contributed to the major share in 2020. By region, on the other hand, the market across Asia-Pacific would cite the fastest CAGR by 2030.

Portland, OR, June 14, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Diabetic Retinopathy Market was estimated at $3.08 billion in 2020 and is expected to hit $10.78 billion by 2030, registering a CAGR of 13.7% from 2021 to 2030. The report provides an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive scenario, and varying market trends.

Download Sample PDF at: https://www.alliedmarketresearch.com/request-sample/2010

Surge in the prevalence of diabetes, rise in the geriatric population, growth in incidence of blindness due to diabetes, and increase in focus on awareness that facilitates early diagnosis to control the diseases drive the growth of the global diabetic retinopathy market. On the other hand, dearth of skilled ophthalmologists and extended approval time for drugs impede the growth to some extent. However, emergence of combined therapies for treatment of diabetic macular edema and the emerging markets of the Asia-Pacific and LAMEA regions are expected to create lucrative opportunities in the industry.

Covid-19 scenario-

  • There was a steep decline in ophthalmic outpatient visits during the pandemic. DR screening was frequently postponed during the pandemic, particularly in areas with high Covid-19 community transmission. This factor impacted the global diabetic retinopathy market negatively,

  • However, as the global situation has gotten better, the market is anticipated to revive soon.

The global diabetic retinopathy market is analyzed across type, treatment type, and region. Based on type, the proliferative diabetic retinopathy segment contributed to nearly three-fifths of the total market revenue in 2020, and is projected to lead the trail by 2030. The Diabetic Macular Edema (DME) segment, however, would exhibit the fastest CAGR of 13.9% during the forecast period.

Specific Requirement on COVID-19? Ask to Our Industry Expert: https://www.alliedmarketresearch.com/purchase-enquiry/2010

Based on treatment type, the laser surgeries segment accounted for more than two-fifths of the total market share in 2020, and is projected to dominate by 2030. The steroid implants segment, on the other hand, would exhibit the fastest CAGR of 14.9% during the forecast period.

Based on region, the market across North America held the major share in 2020, garnering nearly two-fifths of the global market. The Asia-Pacific region, on the other hand, would manifest the fastest CAGR of 14.4% throughout the forecast period.

The key market players analyzed in the global diabetic retinopathy market report include Ampio Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc. (Bausch Health Companies Inc.), Bayer AG, Kowa Co., Ltd., Novartis, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Alimera Science, Inc., F-Hoffmann-La Roche Ltd., and Abbvie, Inc. These market players have adhered to several strategies including partnership, expansion, collaboration, joint ventures, and others to prove their flair in the industry.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Request for 14 days free trial: https://www.alliedmarketresearch.com/avenue/trial/starter

“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”

Trending Reports in Healthcare Industry (Book Now with 10% Discount):

Advanced Wound Care and Closure Market - Global Opportunity Analysis and Industry Forecast, 2020-2030

Flow Cytometry Market - Global Opportunity Analysis and Industry Forecast, 2020-2030

Point of Care Diagnostics Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

Mechanical Ventilators Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

Healthcare IT Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

3D Printing Healthcare Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

Ultrasound Devices Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

Remote Patient Monitoring Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

Dental Consumables Market - Global Opportunity Analysis and Industry Forecast, 2020–2030

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

CONTACT: Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com/reports-store/life-sciences Follow Us on LinkedIn: https://www.linkedin.com/showcase/life-sciences-industry-research/